KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications – Raw experimental data pt. 2

Raw experimental data for “KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications” accepted for publication in Haematologica (2026) – part 2. Detailed descirption of experimental procedures is available in Zenodo (https://doi.org/10.5281/zenodo.21492388).

1. RT-qPCR evaluation of KSR2 expression in T-ALL cell lines upon CRISPR inhibition-mediated blockade of its intronic regulatory region, undergoing to DNA demethylation in KSR2-positive cells.
2. RT-qPCR evaluation of TAL1 and KSR2 expression in T-ALL cell lines upon short hairpin RNA-mediated repression of TAL1 transcription factor in JURKAT T-ALL cell line.
3. Evaluation of the cytotoxicity of KSR2 small molecule inhibitor APS-2-79 in T-ALL cell lines, using Cell Counting Kit-8 assay.